Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
Cancer Medicine · 2024-07 · 13 (14)
DOI: 10.1002/cam4.7378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 19.07.2024. Verfasst von Dian Jin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Monocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Zhejiang Key Research and Development Project.
Abstract (Originalsprache)
Introduction
Although the combination of venetoclax (VEN) and hypomethylating agents (HMAs) results in impressive efficacy in acute myeloid leukemia (AML), there is still a subset of patients who are refractory. We investigated the outcomes of AML patients with monocytic differentiation who were treated with frontline VEN/HMA.
Methods
A total of 155 patients with newly diagnosed AML treated with frontline VEN/HMA were enrolled in the study. Monocyte‐like AML was identified by flow cytometry with typical expression of monocytic markers, and M5 was identified according to French, American, and British category. We compared the outcomes of patients with different characteristics.
Results
The rate of complete remission (CR) and CR with incomplete recovery of blood counts (CRi), progression‐free survival (PFS), and overall survival (OS) in monocyte‐like AML were inferior to those in nonmonocyte‐like AML (CR/CRi rates, 26.7% vs. 80.0%, p < 0.001; median PFS, 2.1 vs. 8.8 months, p < 0.001; median OS, 9.2 vs. 19 months, p = 0.013). CR/CRi rate in M5 was lower than that in non‐M5 (60.7% vs. 75.5%, p = 0.049). Multivariate analyses showed that monocyte‐like AML was associated with lower odds of CR/CRi and higher risk of progression.
Conclusion
Our study suggested that newly diagnosed AML with a monocytic immunophenotype had a poor prognosis with VEN/HMA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Hematology, Ningbo Medical Treatment Center Li Huili Hospital, Ningbo, China.
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
- Institute of Hematology, Zhejiang University, Hangzhou, China.
- Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
ORCID-Profile: Dian Jin, Jingsong He, Zhen Cai
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
- Zhejiang Key Research and Development Project
Zitieren
APA
Jin, D., He, J., Chen, H., Wu, W., Han, X., Le, J., Shu, W., Yang, Q., Pei, S., Cai, Z., & He, D. (2024). Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents. Cancer Medicine, 13(14). https://doi.org/10.1002/cam4.7378
Vancouver
Jin D, He J, Chen H, Wu W, Han X, Le J, et al. Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents. Cancer Medicine. 2024;13(14). doi:10.1002/cam4.7378
BibTeX
@article{Jin2024,
author = {Jin, Dian and He, Jingsong and Chen, Haoguang and Wu, Wenjun and Han, Xiaoyan and Le, Jing and Shu, Wenxiu and Yang, Qianqian and Pei, Shanshan and Cai, Zhen and He, Donghua},
title = {Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {14},
doi = {10.1002/cam4.7378}
}
EUVIMED